| Ytd | -25.84% | |
| 1y | -66.28% |
| Open | 2.61 | Prev Close | 2.61 | Low | 2.56 | High | 2.66 | Mkt Cap | 40.02M |
| Vol | 116.77K | Avg Vol | 499.13K | EPS | -11.03 | P/E | -0.24 | Forward P/E | N/A |
| Beta | 2.53 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.98 | 200-d Avg | 3.72 | 1yr Est | 0.00 |
HYPD News
LAGUNA HILLS, Calif. , July 29, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperi
Deployment of 500,000 HYPE Expands Client Service and Revenue Opportunities Positions Company as Bon
Deployment of 500,000 HYPE Expands Client Service and Revenue Opportunities Positions Company as Bo
DALLAS, June 22, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the
Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analys
DALLAS, June 08, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the
Hyperion DeFi, Inc. (HYPD) Q1 2026 Earnings Call Transcript
Company Reports Record $8.8M Net Income and $19.5M Adjusted EBITDA ( 8 ) Treasury Exceeds 2.00M HYPE
DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the
DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the
LAGUNA HILLS, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion
LAGUNA HILLS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperi
Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Neuren Pharmaceuticals (OTCMKTS:NURPF - Get Free
Hyperion DeFi, Inc. (HYPD) Q4 2025 Earnings Call Transcript
Five Diversified, Ramping DeFi Business Lines Delivered Growth Exceeding Q4 Guidance Treasury Exceed
Shares of Hyperion DeFi, Inc. (NASDAQ: HYPD - Get Free Report) have earned an average rating of "Hol
Unlocks Cost-Optimized On-Chain Credit Access, Additional Ecosystem Rewards, and Expanded Revenue Op
Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Zelira Therapeutics (OTCMKTS:ZLDAF - Get Free Rep
Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Faron Pharmaceuticals Oy (OTC: FPHAF - Get Free R
Hyperion DeFi, Inc. (NASDAQ: HYPD - Get Free Report) has received a consensus rating of "Hold" from